Cleared and launched in Europe earlier this year, the Unify cardiac resynchronization therapy defibrillator (CRT-D) and Fortify implantable cardioverter defibrillator (ICD) from St. Jude Medical are now also FDA approved. The devices cram in more energy into smaller footprints, and feature advanced sensing technology and more anti-tachycardia pacing options.
More about Unify and Fortify from the press release:
The Unify CRT-D and Fortify ICD have 45J of stored energy and can deliver 40J, the highest energy of any ICD available today. This high energy capacity gives these devices the ability to provide a greater safety margin, which could increase the chances that therapy will be successful for patients who may need more energy to correct their heart rhythm.
The devices’ narrow shape, along with their small footprint, allows physicians to implant them using a smaller incision, leading to less time spent closing the incision and a reduced scar for the patient. The company’s SJ4 lead connector system further streamlines the procedure by reducing the number of set screws and connections between the defibrillation lead and the device, which can improve patient comfort by reducing the bulk of wires in the patient’s chest.
Both devices also have features designed to reduce inappropriate or unnecessary defibrillation therapy, while ensuring effective therapy occurs when the patient needs it. The features include advanced sensing technology and more anti-tachycardia pacing options, which can convert many fast ventricular arrhythmias painlessly and avoid the need for high voltage shocks.